SUBSCRIBE: Print / Digital / eNewsletter
Officials with the FDA have granted approval to ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of relapsing multiple sclerosis.
Crisaborole ointment, 2% (Eucrisa, Pfizer) has been approved for use in pediatric patients with atopic dermatitis as young as 3 months of age.
Officials with the FDA have approved a 420-mg multi-dose of trastuzumab-bttb (Ontruzant, Samsung Bioepis), a biosimilar referencing trastuzumab (Herceptin).
The FDA issued emergency use authorization of a rapid, point-of-care COVID-19 diagnostic test, developed by Cepheid, that has a detection time of approximately 45 minutes.
Analysts have forecasted the market for NASH drugs could reach $20 billion by 2025.
Dr. Reddy’s Laboratories has launched its ziprasidone mesylate 20 mg/mL for injection, the first generic version of Geodon (Pfizer) for injection.
On December 23, 2019, the FDA approved ubrogepant for the acute treatment of migraine with and without aura in adult patients.
Empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) is being investigated to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease.
Sebela Pharmaceuticals has announced the FDA approval of lactitol (Pizensy), an oral solution for treating chronic idiopathic constipation (CIC) in adults, according to their press release.
Nintedanib (Ofev, Boehringer Ingelheim Pharmaceuticals) has been approved for the treatment of chronic fibrosing interstitial lung disease with a progressive phenotype.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
